| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/01/2003 | CN1388118A Substituted phenyl alkyl nitrogen monoxide synthase inhibitor and its prepn and use |
| 01/01/2003 | CN1387910A Natural medicated health food for preventing and treating diabetes and cardiac vascular diseases |
| 01/01/2003 | CN1387904A Blood pressure reducing and stabiliaing Chinese medicine and its prepn |
| 01/01/2003 | CN1387903A Cardiac and cerebral blood vessel nourishing tea |
| 01/01/2003 | CN1387893A Sugar-free erigeron breviscapus granule and its prepn and application |
| 01/01/2003 | CN1387887A Chinese medicine prepn for treating arterioscleriosis |
| 01/01/2003 | CN1387883A Chinese medicine extract and its application |
| 01/01/2003 | CN1387880A Blood circulation promoting wine |
| 01/01/2003 | CN1387874A Sanjiangcha tea of ten kinds of chinese medicine materials and its making process |
| 01/01/2003 | CN1387859A Antilipemic Chinese medicine capsule |
| 01/01/2003 | CN1387854A Dispersed general arasaponin tablet and its prepn and application |
| 01/01/2003 | CN1387849A Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (NIDDM) attack |
| 01/01/2003 | CN1387848A Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (NIDDM) attack |
| 01/01/2003 | CN1387795A Nutrient flour special for diabetes and hypertension patients |
| 01/01/2003 | CN1097579C Ortho-substituted benzoylguanidines, process for their preparation, use and medicine containing them |
| 01/01/2003 | CN1097468C Products containing G-CSF and TNF binding protein |
| 01/01/2003 | CN1097457C Treatment and prevention of untoward effect to reactive oxygen component |
| 12/31/2002 | US6500863 Interleukin binding inhibitors such as n-(2-hydroxyl-3-amino sulfonyl-4-chlorophenyl)-n'-(2-bromophenyl)urea, used for prophylaxis of chemokine mediated diseases |
| 12/31/2002 | US6500859 Administering microtubule stabilizing chemotherapeutic agent for prophylaxis of arterial disease |
| 12/31/2002 | US6500856 For therapy of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators |
| 12/31/2002 | US6500855 Nitrogen containing aromatic heterocycles with ortho-substituted p1 groups; anticoagulants |
| 12/31/2002 | US6500851 Antithrombotic agents |
| 12/31/2002 | US6500845 Activating cytokine release using immunosuppressants such as 2-(3-methyl-2-oxo-piperidin-3-yl)-benzo(d)isoselenazol-3-one, racemic mixtures or isomers having dimensional stability, prepared in the presence of reducing agent |
| 12/31/2002 | US6500839 CRF receptor antagonists and methods relating thereto |
| 12/31/2002 | US6500835 Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
| 12/31/2002 | US6500830 Conversion of modification D to modification A of doxazosin mesylate |
| 12/31/2002 | US6500828 Triazolo-pyridazine derivatives as ligands for gaba receptors |
| 12/31/2002 | US6500825 Substituted 2-aminoacetamides and the use thereof |
| 12/31/2002 | US6500823 Energy deficiency of the cell caused by parp inhibition, in diabetes complications, in oxygen deficient status of the heart and brain, in neurodegenerative diseases, in the treatment of autoimmune and/or viral diseases |
| 12/31/2002 | US6500818 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 12/31/2002 | US6500811 Prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved; these include degenerative joint disorders such as osteoarthroses and disorders of connective tissue |
| 12/31/2002 | US6500803 Factor VIIa inhibitors |
| 12/31/2002 | US6500672 A competitive assay for binding activity to recombinant hepatocyte nuclear factor-4 receptors, a chimeric receptor comprising the ligand binding domain of a hnf-4 receptor and dna binding domain of another receptor |
| 12/31/2002 | US6500654 Cardiac-related ankyrin-repeat protein kinase |
| 12/31/2002 | US6500454 Dosage form of timed, sustained release beads comprising core particle of propranolol coated with ethyl cellulose membrane to sustain drug release and outer membrane comprising mixture of ethyl cellulose and enteric polymer providing lag time |
| 12/31/2002 | US6500450 Composition for treating migraine headaches |
| 12/31/2002 | US6500431 Inhibitors of angiogenesis and tumor growth |
| 12/31/2002 | CA2097732C Composition comprising r-alpha-lipoic acid and vitamin e for treating diabetes mellitus |
| 12/28/2002 | CA2391205A1 Benzoic acid substituted benzopyrans for the treatment of atherosclerosis |
| 12/27/2002 | WO2002103355A1 Preventives/remedies for heart diseases |
| 12/27/2002 | WO2002103031A2 Methods for detecting and treating the early onset of aging-related conditions |
| 12/27/2002 | WO2002103027A1 Glycoprotein and process for producing the same |
| 12/27/2002 | WO2002103014A2 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 12/27/2002 | WO2002102997A2 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same |
| 12/27/2002 | WO2002102990A2 Fibroblast growth factor and nucleic acid encoding same |
| 12/27/2002 | WO2002102978A2 Human growth hormone antagonists |
| 12/27/2002 | WO2002102822A1 Adenosine derivative in polymorph ii form |
| 12/27/2002 | WO2002102821A1 Adenosine derivative in polymorph i form |
| 12/27/2002 | WO2002102808A2 (PYRIDO/THIENO)-[f]-OXAZEPIN-5-ONE DERIVATIVES AS POSITIVE MODULATORS OF THE AMPA RECEPTOR |
| 12/27/2002 | WO2002102805A1 NEW USE Of CYCLOLIGNANS AND NEW CYCLOLIGNANS |
| 12/27/2002 | WO2002102804A1 New use of specific cyclolignans |
| 12/27/2002 | WO2002102800A1 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| 12/27/2002 | WO2002102794A2 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | WO2002102788A1 Crystalline salts of benzoylbenzofuran-derivatives |
| 12/27/2002 | WO2002102787A2 Novel sulfonic acid derivatives |
| 12/27/2002 | WO2002102782A2 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE |
| 12/27/2002 | WO2002102780A1 Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient |
| 12/27/2002 | WO2002102778A1 Phenylpyridine carbonyl piperazine derivative |
| 12/27/2002 | WO2002102771A1 Tryptase inhibitors |
| 12/27/2002 | WO2002102770A1 Novel aliphatic compound, method of synthesis, and method of utilization |
| 12/27/2002 | WO2002102397A1 Use of an extract of the root of balloon-flower for preventing and treating a degenerative brain disease or for enhancing memory |
| 12/27/2002 | WO2002102394A2 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
| 12/27/2002 | WO2002102391A2 Composition comprising nanoparticulate spironolactone |
| 12/27/2002 | WO2002102390A1 Enhanced drug delivery in transdermal systems |
| 12/27/2002 | WO2002102386A1 Methods and pharmaceuticals for treating muscle insulin resistance and related conditions |
| 12/27/2002 | WO2002102383A1 Aqueous cilostazol preparation for injection |
| 12/27/2002 | WO2002102381A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage |
| 12/27/2002 | WO2002102375A2 Imidazole derivatives for modulating sodium channels |
| 12/27/2002 | WO2002102364A1 Pparg agonistic medicinal compositions |
| 12/27/2002 | WO2002102360A2 Compositions based on branched chain amino acids for improving the myocardial ventricular function in patients suffering from diabetes |
| 12/27/2002 | WO2002102315A2 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 |
| 12/27/2002 | WO2002102314A2 Purine inhibitors of phosphodiesterase (pde) 7 |
| 12/27/2002 | WO2002102313A2 Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| 12/27/2002 | WO2002102310A2 Proteins associated with cell growth, differentiation, and death |
| 12/27/2002 | WO2002083696A3 Novel cyclo azaphospha hydrocarbons |
| 12/27/2002 | WO2002076946A3 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain. |
| 12/27/2002 | WO2002070473A3 Carboxamide derivatives as therapeutic agents |
| 12/27/2002 | WO2002062335A3 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
| 12/27/2002 | WO2002060454A3 Use of dinucleoside polyphosphate to stimulate removal of fluid in retinal disorders |
| 12/27/2002 | WO2002056874A3 Lipid-based nitric oxide donors |
| 12/27/2002 | WO2002055099A3 Modulation of pericyte proliferation using bpi protein products or bpi inhibitors |
| 12/27/2002 | WO2002055087B1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain |
| 12/27/2002 | WO2002053142A3 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines |
| 12/27/2002 | WO2002051420A3 Methods and formulations for the treatment of female sexual dysfunction |
| 12/27/2002 | WO2002046181A3 Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 12/27/2002 | WO2002045695A3 Hydrostatic delivery system for controlled delivery of agent |
| 12/27/2002 | WO2002020030A3 Use of buchu extracts for hypertension |
| 12/27/2002 | WO2002018445A8 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 12/27/2002 | WO2002004623A3 ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE |
| 12/27/2002 | WO2001097829A3 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| 12/27/2002 | WO2001085937A3 Regulator of g protein signalling (rgs8) |
| 12/27/2002 | WO2001021574A9 Systems and methods for opening obstructed biological conduits |
| 12/27/2002 | CA2782868A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782865A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782862A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782857A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782791A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782761A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782628A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782623A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |